An observational study in Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes and Diabetes, sponsored by Jaeb Center for Health Research. Recruiting at 18 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Jaeb Center for Health Research · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.
Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 52nd largest by planned enrollment of the 193 observational ones that give a count, is one of 20 that started in 2025, is one of 194 observational ones, reaches primary completion later than 91 of the 108 other live ones, and was the 686th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
Aimmune Nestlé Health Science US R&D, LLC · Sites in United States, Bulgaria, Hungary and 4 more countries
Ages 18–85
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 3–18
Ghady Haidar · Sites in United States
Ages 18+
Anagram Therapeutics, Inc. · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
717 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 143 · Phase 3 108 · Phase 4 47
First in 1988; this study’s year is marked. 20 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 86 across 504 observational studies indexed under Cystic Fibrosis.
Median enrollment 36 across the 517 interventional studies, 80 across the 193 observational. Of the 569 that completed or were terminated, 263 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
250 of 717 have an industry lead sponsor. The 10 most frequent:
Jaeb Center for Health Research is the lead sponsor of 129 studies on the registry; 16 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Jaeb Center for Health Research has 3 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
43 of the studies in Cystic Fibrosis with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413368Phase 3Children's Hospital Los AngelesMaralixibat in Patients With Cystic Fibrosis and Constipation | 2027-06-30 |
| NCT06449677Phase 3Jaeb Center for Health ResearchBionic Pancreas in CFRD | 2027-06-30 |
| NCT06996951Phase 3Indiana UniversitySinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy | 2027-07 |
| NCT06237335ReCode TherapeuticsA Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 43 to your calendar (.ics) → With an account.
Among the 717 studies in Cystic Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter cross-sectional study will include a diverse population of adolescents and adults with CF.
The overall Aim is to describe prevalence of diabetes microvascular complications and macrovascular surrogates in people with established CFRD.
Individuals with CFRD diagnosis ≥ 5 years at time of enrollment
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pulse Wave Velocity Exclusion Criteria:
Possible exclusions based on investigator medical provider assessment (additional precautions may be followed to allow inclusion):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals diagnosed with Cystic Fibrosis-Related Diabetes for more than 5 years before enrollment
Other: observational study
This is an observational study.
Microvascular Complications
To describe the rates of microvascular complications (retinopathy, nephropathy, and peripheral neuropathy) and their relationships with HbA1c and diabetes duration in diverse cohort of adolescents and adults with CFRD for ≥5 years.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Macrovascular Surrogates
To describe macrovascular surrogates (resting blood pressure (BP), fasting lipids) and their relationship with HbA1c, diabetes duration and BMI in a diverse cohort with established CFRD.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
PhenX English Proficiency
This questionnaire will be used to describe the social determinants of health in the study population and their cross-sectional relationships with microvascular complications and macrovascular surrogates will largely be explored.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
PhenX Food Security & Prescription Accessibility
This questionnaire will be used to describe the social determinants of health in the study population and their cross-sectional relationships with microvascular complications and macrovascular surrogates will largely be explored.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Exercise and Substance Use
This questionnaire ask questions regarding participants' physical activity, sleeping habits and substance use.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Pubertal Self-Assessment
A self-evaluation questionnaire to assess child's pubertal development.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Beverage Questionnaire (BEVQ15)
A questionnaire that asks the frequency and amount of beverage intake for the past month.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
CFRD Care & Technology
This is a questionnaire that asks participants regarding their CFRD care and the technology they use to help them manage diabetes.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Diabetes Management Experience
This is a questionnaire that asks how participants manage their diabetes for the past 12 months.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Problem Areas in Diabetes (PAID)
Questionnaire that asks participants about possible diabetes-related issues they have experienced.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Problem Areas in Diabetes Parents of Teens (P-PAID-T)
Questionnaire about what the parent or guardian of a participant may experience with their child's diabetes and rating how true it is for them over the past month.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Hypoglycemia Fear Survey (Child)
A survey that consists of 25 questions and selecting from scale (0 = never to 4 = always) about how low blood sugar makes children feel and do.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Hypoglycemia Fear Survey (Parent)
Survey that consists of 25 questions about the frequency of things parents of children with diabetes sometimes do to keep from having low blood sugar.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Hypoglycemia Fear Survey (Adult-Short Form)/Worry (HFS-II-Worry)
A survey about various scenarios that may happen to the participant and rating how true it is for them over the past 6 months.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Gold Score
A 7 item scale that measures hypoglycemia awareness
Time frame: From enrollment to the end of the participant's participation or 4 weeks
All of Us
A questionnaire that consists of 14 questions asking about the participant, their work and their home life.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Continuous glucose monitoring (CGM)-defined glycemic control (time-in-range, time-above-range, time-below-range, glucose variability), and the relationships between CGM metrics and HbA1c, in a diverse population of people with established CFRD
This will be measured using a continuous glucose monitor that will be worn by the participant for 3 to 10 days.
Time frame: 3-10 days
Diversity of participants enrolled and barriers to enrollment
This will be measured using the patient-related outcomes questionnaires.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Renal function by eGFR
Function will be assessed by collection of creatinine and Cystatin-C
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Liver function
This will be measured by liver enzymes and complete blood count (CBC); APRI and EMR data for liver imaging
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Exploratory Outcome - Participant diversity
This will measure diversity of individuals who were approached for study inclusion, who were recruited, who consented and who partially or fully completed study procedures as well as barriers and facilitators to recruitment.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Cardiovascular sub-study - Pulse Wave Velocity and Pulse Wave Analysis (PWV & PWA)
A Sphygmocor XCEL device will be used to measure PWV/PWA (m/sec), pulse pressure amplification and augmentation index (Aix) and Aix adjusted to a HR of 75 (Aix-75).
Time frame: 1 study visit day
Exploratory Outcome - HbA1c and CGM metrics with nutritional intake
The participant will complete 3-day recall of food intake using NIH's Automated Self-Administered 24-Hour (ASA24) Dietary Assessment Tool.
Time frame: 3 days
Exploratory Outcome - HbA1c and CGM metrics with physical activity
The participant will be required to wear an accelerometer device for 3 to 10 days to assess physical activity.
Time frame: 3-10 days
Cardiovascular sub-study - Ambulatory Blood Pressure Monitoring
An oscillometric Spacelab monitors will be used to measure variables including SBP/DBP and BP load (%BP above 95th percentile for sex and height) for the 24-hour period and awake/sleep period. Sleep time will be determined from actigraphy and participant documentation.
Time frame: 24 hours
Fecal Collection
Participant stool sample will be obtained for fecal elastase only for those for pancreatic sufficiency status is unclear.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Sample Collection for Biorepository
Blood, urine and stool will be collected for biorepository.
Time frame: From enrollment to the end of the participant's participation or 4 weeks
Information Collection for Geocoding
The study will use the participants' addresses or part of their addresses (such as their zip codes) to allow researchers to look at how where they live might be related to their health through geocoding.
Time frame: from enrollment
Plan to share: Undecided
Started Sep 2025 (actual). Primary completion is estimated for Nov 2028, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research →